Actively Recruiting
A Real-world, Longitudinal Observational Study of the Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada
Led by Chronicle Academy · Updated on 2026-01-27
80
Participants Needed
6
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a multi-centre, open-label, prospective observational study across Canada to evaluate the real-world impact, safety, and effectiveness of tildrakizumab in patients with moderate-to-severe plaque psoriasis. The study focuses on patients with Fitzpatrick skin types III and above, aiming to address the limited documentation of tildrakizumab's effects in Canada's diverse population. The findings will help improve care and ensure treatment outcomes reflect this population's needs. Participants will be patients initiating tildrakizumab as part of their routine care through the ILUMYA SUPPORT® Program. The study will last 52 weeks, during which all enrolled patients will be observed without receiving additional interventions from the study team. The decision to start tildrakizumab treatment must occur independently before joining the study. During the study, participants will attend visits where researchers will assess quality of life using the Dermatology Life Quality Index (DLQI), monitor psoriasis severity through measures like PASI, Body Surface Area, and Physician Global Assessment, and evaluate treatment impact on sleep, discomfort, and skin pain. Safety and adherence will be tracked throughout the 52-week period. The primary outcome focuses on DLQI changes at 16 weeks, with extended assessments continuing to week 52.
CONDITIONS
Brief Title
Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Diagnosed with moderate-to-severe chronic plaque-type psoriasis with Fitzpatrick skin type III or above and Body Surface Area (BSA) ≥3%
- Candidate for phototherapy and/or systemic therapy
- Planning to start tildrakizumab treatment through the ILUMYA SUPPORT® Program and have not yet received the first dose
- Decision to treat with tildrakizumab made independently before study recruitment
- Able to read, understand, and communicate in English
- Willing and able to provide informed consent and comply with study procedures
You will not qualify if you...
- Known allergy to tildrakizumab, its ingredients, or container components
- Currently taking oral psoriasis medications such as methotrexate, cyclosporin, or acitretin
- Diagnosed only with palmoplantar psoriasis
- Medical conditions or significant health issues that could affect participation or study assessments
- Women of childbearing potential who are pregnant, planning pregnancy, or breastfeeding
- Participating or recently participated (within 30 days) in other interventional clinical trials
- Unable or unwilling to comply with study procedures, including completing questionnaires
- Any other conditions that could pose safety risks or interfere with study results as determined by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 52 weeks
Participants who start tildrakizumab treatment through routine care are observed to evaluate treatment impact and safety over time.
Visits at baseline, Week 16, and Week 52
Trial Site Locations
Total: 6 locations
1
Burlington Skin and Wellness
Burlington, Ontario, Canada, L7L 3E5
Actively Recruiting
2
Locke Dermatology
Hamilton, Ontario, Canada, L8P 4B4
Actively Recruiting
3
Panorama Dermatology Clinic
Kanata, Ontario, Canada, K2T 0N7
Actively Recruiting
4
Centricity Research London Victoria Multispecialty
London, Ontario, Canada, N6A 2C2
Actively Recruiting
5
Factor Dermatology
Ottawa, Ontario, Canada, K2A 3Z3
Actively Recruiting
6
Saskatoon Dermatology Centre
Saskatoon, Saskatchewan, Canada, S7T0G3
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here